Humana Inc vs Petróleo Brasileiro SA — how do they compare? Humana Inc trades at $445 (market cap $47.61B), while Petróleo Brasileiro SA trades at $24.51 (market cap $149.03B). The key difference: Petróleo Brasileiro SA is far larger — about 3.1× Humana Inc's market cap, and Petróleo Brasileiro SA pays the higher dividend (6.98%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Petróleo Brasileiro SA for 25 Days on average.
| HUM | PBR | |
|---|---|---|
Market Cap | $47.61B | $149.03B |
Volume | 1,827,332 | 30,322,411 |
Sector | Health | Energy |
52-Week High | $409.85 | $24.69 |
52-Week Low | $163.67 | $11.54 |
Typical Hold Time | 53 Days | 25 Days |
Enterprise Value | $54.97B | $209.45B |
Dividend Yield | 0.89% | 6.98% |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
Petrobras (PBR) trades at $23.99, up 0.8% with strong bullish technical signals from moving averages. The company shows robust fundamentals with a P/E of 6.06, net income margin of 24.52%, and ROE of 30.77%. Recent Q2 2026 earnings beat expectations at $1.62 EPS versus $1.52 expected. Positive developments include new oil discoveries and platform deployments boosting production capacity.
PBR presents compelling value with attractive valuation metrics and strong profitability, though current price sits near analyst consensus target of $22.33. Key risks include political interference in Brazil and capital expenditure pressures. The stock offers dividend yield potential with recent $0.53 dividend declaration, supported by 50% analyst buy ratings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →